Just a week after NeuroSearch failed a phase II pain trial (ABT-894), they’ve inked a collaboration which will focus on new CNS therapeutics based upon defined ion channel targets
NeuroSearch is eligible to receive equity payments and research funding of up to USD 30 million over the three years of the alliance.
Terms
————————–
Upfront: $5M
Potential Research Funds: $8M
Equity: $17M
Milestones: Up to $320M if all drugs reach the clinic
————————–
NeuroSearch will be responsible for the drug discovery programmes under the collaboration and potentially early development of novel drug candidates. Lilly will have various options to exercise license rights to individual compounds covered by the agreement and related intellectual property. Upon exercise of license rights, Lilly will be responsible for all subsequent development and commercialisation activities. For each product, successfully developed and commercialized under the alliance, NeuroSearch may be entitled to milestone payments of up to USD 320 million (DKK 1,868.2 million) plus royalties on the product’s global sales.
NeuroSearch, Lilly ink multimillion-dollar CNS deal
(Via Fierce Biotech.)
Theoretically Related Posts
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Add New Comment
Thanks. Your comment is awaiting approval by a moderator.
Do you already have an account? Log in and claim this comment.
Add New Comment
Trackbacks
(Trackback URL)